Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.01
-
Shares outstanding
-
27.4M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
10.3M
-
Shares change
-
+91.4K
-
Total reported value, excl. options
-
$90.8M
-
Value change
-
-$665K
-
Put/Call ratio
-
0.19
-
Number of buys
-
40
-
Number of sells
-
-41
-
Price
-
$8.81
Significant Holders of ICAD, INC. - Common Stock, par value $0.01 (ICAD) as of Q3 2020
101 filings reported holding ICAD - ICAD, INC. - Common Stock, par value $0.01 as of Q3 2020.
ICAD, INC. - Common Stock, par value $0.01 (ICAD) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.3M shares
of 27.4M outstanding shares and own 37.6% of the company stock.
Largest 10 shareholders include BlackRock Inc. (1.41M shares), G2 Investment Partners Management LLC (1.11M shares), VANGUARD GROUP INC (1.06M shares), FEDERATED HERMES, INC. (650K shares), Parkman Healthcare Partners LLC (582K shares), Portolan Capital Management, LLC (488K shares), RENAISSANCE TECHNOLOGIES LLC (382K shares), Fairpointe Capital LLC (373K shares), Schonfeld Strategic Advisors LLC (338K shares), and WELLINGTON MANAGEMENT GROUP LLP (307K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.